Edit Module

Zoetis Earns License for Cytopoint Skin Therapy

The newly branded therapy, formally known as Canine Atopic Dermatitis Immunotherapeutic, is formulated to target and neutralize interleukin-31 (IL-31).


Published:

Zoetis

Apoquel, say hello to your baby brother Cytopoint.

Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”

If the indication sounds familiar, it may be because Cytopoint earned a conditional license in August 2015, when it was known as Canine Atopic Dermatitis Immunotherapeutic. Cytopoint is injected every four to eight weeks.

The newly branded therapy is formulated to target and neutralize interleukin-31 (IL-31). The atopic dermatitis drug Apoquel (oclacitinib tablet) is designed to quickly rid dogs of the urge to itch.

Edit Module
Edit ModuleShow Tags

Archive »Read More

Zoetis, AAVMC Announce 315 Scholarships to Vet Students

The winners of the 2017 Zoetis Veterinary Student Scholarship Program were presented at the 2017 Student American Veterinary Medical Association.

IDEXX Initiative Seeks to Minimize Radiation Risks

Lower the Dose aims to help the veterinary industry improve in-practice radiation safety.

Kansas State Vets Perform Cataract Surgery on Young Gibbon

It might be the first surgery in the world on a gibbon that young.
Edit Module
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module